Then, the clinical relevance of Treg.Sig was determined, and the PD-L1 expression, tumor immune dysfunction and exclusion (TIDE) score, and immune landscape underlying the Treg.Sig were further analyzed. This evidence concerns the gene CD274 and neoplasm.